WO2006133533A1 - Traitement pour le syndrome de l'intestin court - Google Patents

Traitement pour le syndrome de l'intestin court Download PDF

Info

Publication number
WO2006133533A1
WO2006133533A1 PCT/CA2005/000948 CA2005000948W WO2006133533A1 WO 2006133533 A1 WO2006133533 A1 WO 2006133533A1 CA 2005000948 W CA2005000948 W CA 2005000948W WO 2006133533 A1 WO2006133533 A1 WO 2006133533A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
bowel syndrome
short bowel
donor
bioequivalent
Prior art date
Application number
PCT/CA2005/000948
Other languages
English (en)
Inventor
James A. Hardin
Andre Gerald Buret
Original Assignee
University Technologies International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Technologies International Inc. filed Critical University Technologies International Inc.
Priority to PCT/CA2005/000948 priority Critical patent/WO2006133533A1/fr
Priority to AU2005332949A priority patent/AU2005332949A1/en
Priority to JP2008516083A priority patent/JP2008543790A/ja
Publication of WO2006133533A1 publication Critical patent/WO2006133533A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • This invention relates generally to compositions and methods for treating or preventing short bowel syndrome (SBS), or conditions involving colonic resection, small bowel resection, and massive small bowel resection.
  • SBS short bowel syndrome
  • Short bowel syndrome is defined as the spectrum of malabsorption which occurs following the surgical resection of a major portion of the small intestine. The syndrome is characterized by a malabsorption of nutrients. SBS affects people of all ages, from premature infants to adults. There are many conditions for which surgical removal of a significant length of small bowel is indicated, leading to SBS, including but not limited to necrotizing enterocolitis (NEC), abdominal wall defects, jejunal ileal atresia, mid-gut volvulus, and inflammatory bowel disease.
  • NEC necrotizing enterocolitis
  • SBS can be caused by many events, for example after surgical intervention for necrotizing enterocolitis (NEC) or volvulus.
  • NEC necrotizing enterocolitis
  • SBS results in decreased nutrient absorption which may lead to decreased growth, failure to thrive, and serious developmental deficits and mortality (Buchman, A. L., et. al., 1994; Strong, S. A., et. al., 1999).
  • children may go on to develop end-stage liver disease secondary to cholestasis induced by long-term total parenteral nutrition.
  • SBS can be caused by many factors, for example, surgical intervention for Crohn's disease and other maladies, and also results in decreased nutrient absorption, and sometimes deficits in certain essential nutrients. This occurs when the distal ileum is removed.
  • the distal ileum expresses the mechanisms for the absorption of certain essential nutrients (for example vitamin B 12 and other fat-soluble vitamins) and absorption of bile salts.
  • SBS is less life threatening than in infants, but can result in serious life style changes, for example chronic diarrhea, chronic dehydration, cramping, dependency on total parenteral nutrition (TPN), infection, and reliance on exogenous supplements such as vitamin B12.
  • EGF treatment augments the mucosal hyperplasia in response to massive small bowel resection (Chaet, M. S., et. al., 1994; Goodlad, R. A., et. al., 1988; Shin, C. E., et.
  • EGF receptor expression is increased in remnant bowel (Avissar, N.
  • Adaptation is impaired in animals with a defective EGF receptor (Helmrath, M. A., et. al., 1997) and intestinal overexpression of EGF enhances adaptation following small bowel resection (Erwin, C. R., et. al., 1999).
  • EGF treatment has been shown to inhibit the rate of enterocyte apoptosis following massive small bowel resection, an effect that may contribute to the ability of EGF to maintain barrier integrity (Stern, L. E., et. al., 2000).
  • L-citrulline is primarily produced by the intestinal breakdown of glutamine, and a decrease in L-citrulline production (Chen, K., et. al., 1996; Dejong, C. H., et. al., 1998), intestinal glutamine uptake (Chen, K., et. al., 1996) and renal citrulline-to-arginine conversion has been reported in rats with massive small bowel resection (Dejong, C. H., et. al., 1998).
  • Intraperitoneal L-arginine administration was reported to increase weight gain, cellular proliferation and structural adaptation in rats with a 90% small bowel resection (Ozturk, H., et. al., 2002).
  • Oral feeding of ornithine alpha-ketoglutarate, a precursor of glutamine and arginine, to rats following massive small bowel resection has been reported to increase intestinal structural adaptation, ornithine decarboxylase activity and ornithine content and plasma and muscle glutamine levels (Dumas, F., et. al., 1998).
  • An aspect of the invention is to provide a composition
  • a composition comprising an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor wherein the ratio of the agonist and L- arginine, bioequivalent thereof, or NO-donor is between 1:454000000 and 1:1 (mole:mole), or between 1:45400000 and about 1:4500 (mole:mole), or between 1:4540000 and 1:45000 (mole:mole) for the treatment or prevention of short bowel syndrome.
  • the composition may be in solid, lyophilized or solution form.
  • the solution may be suitable for oral delivery to a human, for example for enteral delivery to a human.
  • the solution may be suitable for intravenous administration.
  • the EGF receptor agonist may be EGF and it may be synthetic, optionally manufactured by chemical synthesis or recombinantly, or derived from natural sources.
  • the composition may comprise L-arginine.
  • the composition may be used in increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the composition may be used in increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the ratio of the EGF receptor agonist and L-arginine, bioequivalent thereof, or NO-donor may be 1 : 100,000 (mole:mole).
  • Another aspect of the invention is to provide a unit dose comprising L-arginine, a bioequivalent thereof, or an NO-donor and an EGF receptor agonist suitable for the oral administration to a subject at risk for, or diagnosed with, short bowel syndrome upon dissolution with a pharmaceutically acceptable liquid.
  • the liquid may be selected from the group consisting of water, saline, infant formula, buffered solution, expressed breast milk, other suitable carriers, and combinations thereof.
  • the ratio of the agonist and L-arginine, bioequivalent thereof, or an NO-donor may be between 1:454000000 and 1:1 (molermole), or between 1:45400000 and about 1:4500 (mole:mole), or between 1 :4540000 and 1 :45000 (mole:mole).
  • the EGF receptor agonist may be EGF and the unit dose may comprise L-arginine.
  • Another aspect of the invention is to provide a unit dose comprising L-arginine, a bioequivalent thereof, or an NO-donor and an EGF receptor agonist suitable for the intravenous administration to a subject at risk for or diagnosed with short bowel syndrome upon dissolution with a pharmaceutically acceptable solution.
  • the ratio of the agonist and L-arginine, bioequivalent thereof, or an NO-donor may be between 1:454000000 and 1:1 (mole:mole), or between 1:45400000 and about 1:4500
  • the EGF receptor agonist may be EGF and the unit dose may comprise L-arginine.
  • Another aspect of the invention is to provide a unit dose comprising L-arginine, a bioequivalent thereof, or an NO-donor and an EGF receptor agonist suitable for the parenteral administration to a subject at risk for, or diagnosed with, short bowel syndrome upon dissolution with a pharmaceutically acceptable solution.
  • the liquid may be selected from the group consisting of water, saline, infant formula, buffered solution, expressed breast milk, other suitable carriers, and combinations thereof.
  • the ratio of the agonist and L-arginine, bioequivalent thereof, or an NO- donor may be between 1:454000000 and 1:1 (mole:mole), or between 1:45400000 and about 1:4500 (mole:mole), or between 1:4540000 and 1:45000 (mole:mole).
  • the EGF receptor agonist may be EGF and trie unit dose may comprise L-arginine.
  • the unit doses of the invention may be used in increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the unit doses may also be used in increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the present invention is to provide a method of treating a patient diagnosed with short bowel syndrome or at risk of short bowel syndrome, the method comprising administering an EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor to a patient in need thereof.
  • the patient may have undergone a resection of the small bowel or will undergo a resection of the small bowel.
  • Another aspect of the present invention is to provide a method of treating or preventing short bowel syndrome in a patient in need thereof, the method comprising enterally administering to the patient an EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor, preferably, at least once daily.
  • the EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor may be administered together in a mixture, for example at least once daily.
  • the EGF receptor agonist may be EGF.
  • the EGF may be synthesized recombinantly or by a synthetic chemical process.
  • the method may comprise L-arginine.
  • the methods of the present invention may be used in increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the methods may also be used in increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the invention is to provide a kit comprising therapeutic amounts of an EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor, and instructions for use in the treatment or prevention of short bowel syndrome.
  • the EGF receptor agonist and L-arginine, a bioequivalent thereof, or NO-donor may be supplied combined in solid form.
  • the kit may also include instructions for the step of dissolving the solid form in a solution suitable for oral administration, for example for intravenous administration.
  • the agonist and L-arginine, a bioequivalent thereof, or an NO-donor may be supplied separately. They may be in the form of a solid or a solution.
  • the instructions may include a step of mixing the agonist and L-arginine, a bioequivalent thereof, or an NO-donor before administration.
  • kits may be used in increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the kits may also be used in increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the invention is to provide a method of treating or preventing SBS in a patient, the method comprising: (i) administering to the patient subcutaneously, or intravenously a composition comprising an EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor over a first treatment period; and (ii) administering to the patient enterally a composition comprising an EGF receptor agonist and L-arginine, a bioequivalent thereof, or an NO-donor over a second treatment period, the second period being subsequent to the first period.
  • the second period may be initiated following resolution of ileus.
  • the enteric administration may include administration by enema or oral administration.
  • the second period may include two phases, a first phase in which the administration is oral, and a second phase in which the administration is by an enema.
  • the administration during the first period may be by intravenous administration and the administration during the second period may be by oral route and done 4 to 6 days after resection.
  • Another aspect of the invention is to provide a method of treating SBS in a patient or treating a patient at risk of SBS comprising delivering an EGF receptor agonist to the intestinal tract of the patient and increasing the in vivo generation of NO within the intestinal tract of the patient.
  • Increasing the in vivo generation of NO may include administering a substrate of nitric oxide synthase to the patient, for example administering an NO-donor.
  • the patient may have had a surgical resection of a major portion of the small intestine.
  • the methods of the present invention may be used in increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • the methods may also be used in increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for treating or preventing short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for preparing a medicament for treating or preventing short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for preparing a medicament for increasing weight gain in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Another aspect of the present invention is to provide a use of an EGF receptor agonist and L- arginine, a bioequivalent of L-arginine, or an NO-donor for preparing a medicament for increasing intestinal absorptive surface area in a person having short bowel syndrome or at risk for short bowel syndrome.
  • Figure 1 is a graph showing weight loss expressed as the percentage of the animal's original weight for the five test groups of rats .
  • Figure 2 is a bar graph showing intestinal width upon autopsy of SBS animals which were untreated (SBS), treated with arginine (arg), treated with EGF (EGF), treated with EGF and arginine (EGF- arginine) and animals not having SBS (control).
  • Figures 3 a, 3b and 3 c are bar graphs showing the gross intestinal morphology on autopsy describing intestinal length, intestinal wet weight and intestinal wet weight/length respectively.
  • Figures 4a and 4b are bar graphs describing villus height and crypt depth in jejunal tissue in control, SBS, arg, EGF and EGF-arg treated animals. Detailed Description of the Invention
  • Comprising as used herein means contains, includes, or is composed of certain elements, but is not limited to only those elements. It is open ended.
  • a pharmaceutical composition comprising EGF and L-arginine means any pharmaceutical composition containing EGF and L-arginine, wherein the composition may also contain other elements, for example, another active ingredient, flavourings, adjuvants and the like.
  • Short bowel syndrome or SBS or short gut syndrome as used herein means a gastrointestinal syndrome characterized by symptoms resulting from the malabsorption of nutrients such as abdominal pain, diarrhea, fluid retention, unintended weight loss, and extreme fatigue following the surgical resection of a significant length of small bowel. Accordingly, as used herein, the term “short bowel syndrome” also includes short gut syndrome and massive small bowel resection. Intestinal hormonal reflexes and feedback loops can be disrupted leading to an increase in the volume of proximal gastric and small bowel secretions and altered motility patterns. Water, sodium and magnesium losses can lead to electrolyte disturbances. Certain specific absorptive functions may also be impaired which are unique to certain parts of the intestine, such as the absorption of vitamin B 12, bile salts and other fat soluble vitamins by the ileum.
  • EGF receptor agonist means any molecule which will produce a biochemical effect when bound to any of the erbB(l-4) receptors, particularly the erbBl receptor, such that any or all of the following effects occur: intestinal glucose transport is increased, the apical surface of the enterocytes (cells lining the lumen of the small intestine) are altered, the colonization and translocation of pathogenic organisms across mucosal surfaces is inhibited, and gut maturation is induced.
  • the molecule is preferably epidermal growth factor. It may otherwise be an antibody, small molecule, protein, peptide, peptidic analogues, or peptidomimetic.
  • Epidermal growth factor or EGF as used herein is a 53-amino acid protein known to be synthesized in the duodenum and salivary glands of normal humans, and expressed in human breast milk. The amino acid sequence of human EGF is:
  • the protein used in the experiments described herein had the foregoing sequence.
  • the EGF used in the present invention is a recombinant human EGF (>97% purity) obtained from Protein Express (Higeta-Shoyu Co. Ltd., Japan).
  • Non-human EGF sequences which act as EGF in humans are also contemplated.
  • Species variants of EGF are thus also included, such as described for mouse, rat and pig (Jorgensen, P. E., et. al., 1998; Nexo, E., et. al., 1985; Pascall, J. C, et. al., 1991; and Simpson, R. J., et. al., 1985), or bovine EGF as cited in U.S. patent application 20030059802, or so-called supra-agonistic chimeras of different EGF receptor ligands (Lenferink, A. E., et. al., 2000).
  • This definition also refers to a polypeptide having substantially the same sequence and activity as purified native epidermal growth factor. This includes recombinantly and chemically synthesized peptides or proteins. This term also refers to proteins varying from the native sequence by substitution with other amino acids or deletion of one or more amino acids, as long as the EGF biological activity is substantially preserved.
  • the definition also includes fragments, peptidic analogues, peptidomimetics of EGF, and acylated forms as in US Pat. No. 5,070,188 as long as the EGF biological activity is substantially preserved. EGF biological activity can be screened by a receptor binding assay, and confirmed using any of the methods indicated above in connection with receptor agonists.
  • a human EGF protein in which the methionine (Met) at position 21 is replaced with isoleucine (He) falls within the scope of "EGF.”
  • Such a protein is denoted hEGF-I 2 i generally, and is generally denoted rhEGF-I 2 i if prepared recombinantly (chemically synthesized hEGF is included in the term "hEGF").
  • hEGF-E ⁇ hEGF-E ⁇ .
  • EGF lacking the last 2 of its normal 53 peptides is generally indicated as EGF 5I .
  • Proteins having an amino acid deletion, for example wherein Trp 49 is absent, are generally denoted with the term "del" (or .DELTA.) and a subscript indicating the position, without altering the numbering of the remaining amino acids.
  • Trp 49 were deleted, the resulting protein would be indicated EGF-.DELTA. 49 .
  • Insertions, increasing the chain length, are generally indicated as substitutions substituting 2 or more amino acids for one, e.g., rhEGF-L/Gis indicates insertion of GIy after the natural Leui 5 .
  • EGF- Xi 6 an EGF of the invention where HiSi 6 has been replaced by another amino acid, with or without other modifications, is generally denoted generically by EGF- Xi 6 .
  • L-Arginine as used herein means the semiessential amino acid (2-amino-5-guanidinovaleric acid) and its salts, e.g., acid addition salts suitable for administration to a mammal.
  • a bioequivalent of L- arginine is a compound which, like L-arginine, is a substrate of nitric oxide synthase which generates NO in vivo, or may be converted to a substrate of nitric oxide synthase such as L-citrulline via the arginine-citrulline cycle or enzymes of the urea cycle.
  • the rate-limiting enzyme in endogenous L-arginine production is argininosuccinate synthase.
  • the main site of endogenous L- arginine production is the kidney, which converts L-citrulline to L-arginine (Boger, R. H., et. al., 2001).
  • Glutamine is converted to L-citrulline in the small intestine (Pita, A. M. ; et. al., 2003), and ornithine alpha-ketoglutarate is a precursor of glutamine (Dumas, F., et. al., 1998).
  • a compound, typically a small organic molecule, capable of donating an NO molecule, an "NO donor" when administered in vivo may also be administered.
  • Such compounds include, but are not limited to, S- nitroso-N-acetyl-penicillamine (SNAP), 3-morpholinosydnonimine (SIN-I), sodium nitroprusside (SNP) 4-phenyl-3-furoxancarbonitrile (PFC), glyceryl trinitrate (GTN), and isosorbide dinitrate (ISDN) (Feelisch, M., 1998; Pacher, P., et. ah, 2003; ZeIl, R., et. al., 2003). NO production can be measured in vitro by the Griess assay (Marion, R. : M., et.
  • Sprague-Dawley rats 250-30Og were housed initially for 7 days to allow acclimatization, and sham gavaged once per day for four days prior to surgery.
  • Animals were randomized into 5 groups: 1) resected and gavaged daily with vehicle (0.9% sterile saline) (SBS), 2) resected and gavaged daily with 1.5 mmoles Arginine /kg/day (Arg), 3) resected and gavaged daily with EGF 100 ug/kg/day (EGF), 4) resected and gavaged daily with EGF 100 ug/kg/day and 1.5 mmoles Arginine /kg/day (EGF- Arg), and 5) controls gavaged daily with vehicle (Con).
  • the EGF- Arg treatment is about 1:100,000 mole:mole.
  • the L-arginine used in this study was the hydrochloride salt of the amino acid with a molecular weight of 210.7 rather than pure L- arginine with a molecular weight of 174.2.
  • surgeries were performed under halothane anesthesia as previously described with 25 cm of remnant small intestine retained (Sham, J., et. al., 2002). Briefly, after laparotomy 25 cm of jejunum extending distally from the ligament of Treitz was measured, the bowel divided at that point and the entire distal bowel removed to the mid portion of the ascending colon just below the right colic artery and an anastomosis performed. Animals were gavaged daily between 9-10 am with study compound in 1 cc of vehicle for 10 days.
  • the EGF used in the present invention is a recombinant human EGF obtained from Protein ExpressTM (Higeta-Shoyu Co. Ltd., Japan). Measurements
  • mice After resection the animals were allowed water for the remainder of the postoperative day, and then dry food ad lib to a maximum of 20 g/day with pair feeding starting on the second day postoperative. Animals and the food in each animal's cage were weighed daily, and food intake quantified. Animals were given 20 grams of regular chow per day. Each set of controls (resected and non resected) plus the three treatment groups were followed as a set of five. If one animal in a group ate less than the 20 grams, then the following days the entire set of five got the weight that the animal ate plus 10%.
  • BRDU bromodeoxyuridme
  • weight loss was expressed as a percentage of original weight and data points were plotted and the slope of each growth curve obtained and compared. Weight loss was significantly greater in all treatment groups and in the untreated SBS group compared to the control group (p ⁇ .001). Furthermore, weight loss was significantly less in animals receiving combination EGF-arginine compared to the untreated SBS group ( ⁇ 0.05). Weight loss did not differ between treatment groups or between untreated SBS animals and animals treated with either EGF or arginme alone.
  • Intestinal width (as a measurement of intestinal diameter) is shown in Figure 2. Intestinal width was significantly increased in animals treated with combined EGF-arginine compared to control animals (p ⁇ 0.05). Intestinal width did not differ between any of the other groups.
  • Figure 3 shows the effect of the various treatments on gross intestinal parameters in animals following sacrifice. Intestinal wet weight per length was significantly increased in all treatment groups and the untreated SBS group compared to controls due to a significant increase in intestinal weight in all groups (p ⁇ 0.01). Intestinal length did not differ between any of the groups. While there was a trend for increased intestinal wet weight in the combined EGF-arginine group compared to the untreated SBS and the EGF and arginine groups, this did not reach statistical significance. Although statistically significant results were not realized, there was a general trend for the EGF and arginine treatment to outperform both the EGF treatment and the arginine treatment.
  • Figure 4 shows villus height and crypt depth in jejunal tissue obtained from Control, SBS, arginine, EGF and EGF-arginine treated animals.
  • Villus height was significantly increased in EGF treated animals compared to controls (p ⁇ 0.05).
  • Villus height did differ between any of the other groups.
  • Crypt depth was significantly increased in the EGF (p ⁇ 0.05), EGF-arginine and untreated SBS groups (p ⁇ 0.01) compared to controls.
  • Crypt depth did not differ between arginine treated animals and controls or between any of the resected groups.
  • EGF-arginine administration was significantly more efficacious in the treatment of SBS than administration of EGF or arginine alone.
  • the combination EGF-arginine treatment resulted in an increased weight gain and increased intestinal absorptive surface area in resected animals compared to EGF or arginine given alone.
  • Weight gain is a primary end-point for this condition and shows the clinical benefit of the treatment.
  • Increased intestinal absorptive surface area is a secondary end-point and is required to achieve the primary end-point. This study demonstrates significant improvement in both primary and secondary end-points for this condition.
  • the present invention establishes the feasibility of treating short bowel syndrome with the combination EGF and arginine. It clearly shows that the combination works in practice by increasing weight gain and increasing the intestinal absorptive surface area of patients suffering from SBS. Prior to this invention, studies using arginine alone to treat SBS were contradictory in that some studies showed benefits while other studies indicated it was detrimental.
  • glucagon-like peptide ⁇ bombesin, insulin-like growth factor 1 OctreotideTM, natural conjugated bile acids, low fat diets and glutamine may have beneficial and/or detrimental effects.
  • the present invention clearly establishes that the combination of EGF and arginine is more efficacious in the treatment of SBS than administration of EGF or arginine alone.
  • compositions for the treatment or prevention of short bowel syndrome are provided.
  • Treatment or prevention of short bowel syndrome involves an EGF receptor agonist, and L-arginine or a bioequivalent thereof.
  • SBS develops as subjects suffer malabsorption after surgery. Therefore, stimulating absorption following surgery should be preventative.
  • EGF receptor agonist and L-arginine are conveniently determined on a molar basis.
  • a bioequivalent of L-arginine if capable of producing, on a molar basis, a greater amount of NO than L-arginine as a substrate of nitric oxide synthase, would be determined on a mole-equivalent basis of the amount of NO the bioequivalent is capable of producing.
  • the amount of NO released by an NO-donor would be determined on a mole-equivalent basis.
  • a method of treating or preventing SBS is provided by delivering an EGF-receptor agonist to the intestinal tract of the patient and increasing the in vivo generation of NO within the intestinal tract of the patient. This may include administration of a substrate of nitric oxide synthase or administration of an NO-donor.
  • a treatment of the present invention would require administration by an appropriate route.
  • an oral route of administration would be most preferred.
  • a unit dose of the two agents would be provided in a suitable container for ready opening and delivery to and mixture with a pharmaceutically acceptable solution such as a dietary product.
  • a suitable amount of the components of the present invention could thus be provided in a powdered or granular form to be added directly to milk or other food.
  • Subjects requiring total parenteral nutrition (TPN) may benefit from receiving these components, either as a separate formula or as components of the TPN composition.
  • the components may be provided in a solution form suitable to be immediately or upon dilution with a suitable solution consumed by the patient.
  • the preceding solutions may be administered to the patient via an orogastric tube.
  • suitable dietary products include water, saline, buffered solutions, oral rehydration solutions, infant formula, and expressed breast milk, other suitable carriers, or combinations thereof. Any solution suitable for oral administration may be used.
  • Additives may be added which act as bystander proteins (i.e. nonactive protein "filler"), which protects the EGF from enzymatic degradation by pancreatic proteases (Playford et al., 1993). For example, casein (a milk protein) has been used for this experimentally (Playford et al., 1993).
  • Other approaches may involve administering with a protease inhibitor to preserve EGF structure and activity.
  • a treatment of the invention may be administered orally, enterally, parenterally, intravenously, subcutaneously, nasally, or by enema. It may be possible to choose an intravenous route for an initial period of treatment as, for example, when initially treating SBS, during which period some patients are incapable of receiving an orally administered treatment.
  • the composition may be prepared as a spray, solution, suspension, colloid, concentrate, powder, granules, tablets, pressed tablets, capsules (included coated and uncoated tablets or capsules), suppository and the like. Delayed release or controlled release formulations are also included.
  • the formulations may include additives such as viscosity adjusting agents, osmosity adjusting agents, buffers, pH adjusting agents, flavorings, stabilizers, colorings, preservatives and the like where required
  • a unit dose would be a dosage suitable for administration in a single administration, i.e , a single feeding of the patient
  • a unit dose of L-argmme administered for instance as a hydrochloride salt of L-Argmme thus includes from about 20 mg/kg/day (.09 mmol/kg/day) to about 2000 mg/kg/day (9 mmol/kg/day), or more preferably from about 100 mg/kg/day (.45 mmol/kg/day) to about 1000 mg/kg/day (4.5 mmol/kg/day), or more preferably from about 200 mg/kg/day (0.9 mmol/kg/day) to about 500 mg/kg/day (24 mmol/kg/day) of L-argmme, or more preferably from about 250 mg/kg/day (1.2 mmol/kg/day) to about 400 mg/kg/day (1.9 mmol/kg/day), or more preferably from about 300 mg/kg/day (1.4 mmol/kg/day) to about 350 mg/kg/day
  • the L-argimne-EGF receptor agonist ratio would be between about 1:454000000 mol EGF receptor agonist/mol L-argmme and about 1:1 mol EGF receptor agonist/mol L-argimne, more likely between 1-45400000 mol EGF receptor agomst/mol L-argmme and about 1:4500 mol EGF receptor agonist/mol L-argmme, more likely between 1 '4540000 mol EGF receptor agonist/mol L- argmme and 1 45000 mol EGF receptor agonist/mol L-argmme It is contemplated that treatment would be administered probably at least once a day, 3 or 4 times per day, or even continuously.
  • Intermittent doses could be administered by any convenient route, e g , bolus infusion, oral preparations discussed elsewhere herein, etc , subcutaneously, or by continuous i v drip. More continual administration would more typically be by i v drip or controlled release implants
  • a treatment of this invention could also be used to prophylactically treat a person at risk for developing SBS.
  • a person at such ⁇ sk would include a patient who has just undergone surgical resection of a major portion of the small intestine. Such treatment may begin as soon as feasible after the surgery, possibly after the completion of surgery Following resection, the bowel typically starts to work after 3 to 4 days It may thus be possible to begin oral treatment starting 4 to 6 days after surgery. If immediate treatment post-surgery is indicated then the treatment may be administered intravenously, possibly followed by oral treatment once bowel function resumes. Accordingly the method of treatment would include a first treatment period followed by a second treatment period.
  • EGF is prepared by a synthetic process, being manufactured by conventional biotechnological or chemical techniques
  • EGF might be obtained from a natural source.
  • the combination of factors of the invention would be provided as a single mixture and administered together, but they could be provided in a kit in separate compartments and mixed for administration, or administered separately Both may be biologically available to the luminal side of epithelial cells of the intestine
  • the unit dose When prepared for mixture with a liquid, as for delivery with water, the unit dose could have a solubility enhancer incorporated thereinto.
  • EGF or equivalent polypeptide is provided as a lyophihzed matenal References
  • Kikuchi K., T. Nagano, H. Hayakawa, Y. Hirata, and M. Hirobe. Detection of nitric oxide production from a perfused organ by a luminol-H 2 O 2 system.
  • Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. J.Pediatr.Surg. 37: 765-769, 2002. Shin, C. E., M. A. Helmrath, R. A. Falcone, Jr., J. W. Fox, K. R. Duane, C. R. Erwin, and B. W. Warner. Epidermal growth factor augments adaptation following small bowel resection: Optimal dosage, route, and timing of administration. J.Surg.Res. 77: 11-16, 1998.
  • Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A abd 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med.Microbiol.Immunol. 2003.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour traiter ou pour prévenir le syndrome de l'intestin court. Cette composition comprend un agoniste du récepteur EGF et de la L-arginine, un bioéquivalent de la L-arginine, ou un donneur de NO. Cette composition permet d'augmenter une prise de poids dans le cas d'un syndrome d'intestin court et d'augmenter une zone de surface d'absorption intestinale. L'invention concerne des doses unitaires, des méthodes de traitement, des utilisations et des trousses associées à cette composition.
PCT/CA2005/000948 2005-06-16 2005-06-16 Traitement pour le syndrome de l'intestin court WO2006133533A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CA2005/000948 WO2006133533A1 (fr) 2005-06-16 2005-06-16 Traitement pour le syndrome de l'intestin court
AU2005332949A AU2005332949A1 (en) 2005-06-16 2005-06-16 A treatment for short bowel syndrome
JP2008516083A JP2008543790A (ja) 2005-06-16 2005-06-16 短腸症候群の治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/000948 WO2006133533A1 (fr) 2005-06-16 2005-06-16 Traitement pour le syndrome de l'intestin court

Publications (1)

Publication Number Publication Date
WO2006133533A1 true WO2006133533A1 (fr) 2006-12-21

Family

ID=37531903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/000948 WO2006133533A1 (fr) 2005-06-16 2005-06-16 Traitement pour le syndrome de l'intestin court

Country Status (3)

Country Link
JP (1) JP2008543790A (fr)
AU (1) AU2005332949A1 (fr)
WO (1) WO2006133533A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists
US9066984B2 (en) 2005-07-08 2015-06-30 Biogen Ma Inc. Sp35 antibodies and uses thereof
WO2016176484A1 (fr) * 2015-04-28 2016-11-03 Children's Hospital Medical Center Utilisation de compositions d'oligosaccharides pour améliorer la prise de poids
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMLI A. ET AL.: "Does L-Arginine induce intestinal adaptation by epithelial growth factor?", ANZ J. SURG., vol. 75, no. 1-2, January 2005 (2005-01-01) - February 2005 (2005-02-01), pages 73 - 75, XP003005560 *
HEBIGUCHI T. ET AL.: "Treatment of short bowel syndrome using growth factors", IGAKU NO AYUMI (JAPANESE), vol. 181, no. 7, May 1997 (1997-05-01), pages 504 - 505, XP008074105 *
ÖZTORK H. ET AL.: "Effects of supplemental L-arginine on the intestinal adaptive response after massive small-bowel resection in rats", PEDIATR. SURG. INT., vol. 18, no. 5-6, September 2002 (2002-09-01), pages 332 - 336, XP003005561 *
SHAM J. ET AL.: "Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome", J. PEDIATR. SURG., vol. 37, no. 5, May 2002 (2002-05-01), pages 765 - 769 *
SIGALET D. ET AL.: "A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome", J. PEDIATR. SURG., vol. 40, no. 5, May 2005 (2005-05-01), pages 763 - 768, XP004901782 *
THOMPSON J.S.: "Epidermal Growth factor and the short bowel syndrome", JPEN, vol. 23, no. 5, September 1999 (1999-09-01) - October 1999 (1999-10-01), pages S113 - S116 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists
US9066984B2 (en) 2005-07-08 2015-06-30 Biogen Ma Inc. Sp35 antibodies and uses thereof
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2016176484A1 (fr) * 2015-04-28 2016-11-03 Children's Hospital Medical Center Utilisation de compositions d'oligosaccharides pour améliorer la prise de poids
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Also Published As

Publication number Publication date
AU2005332949A1 (en) 2006-12-21
JP2008543790A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2006133533A1 (fr) Traitement pour le syndrome de l'intestin court
US8278267B2 (en) Method of modifying food preference comprising administering amylin or amylin agonist
US20080248999A1 (en) Amylin formulations
RU2351359C2 (ru) Применение оксинтомодулина, способ и фармацевтическая композиция для профилактики или лечения избыточной массы тела
ES2325773T5 (es) Tratamiento de la obesidad y de los trastornos relacionados
ES2367113T3 (es) Modificación del comportamiento alimentario y control del peso por oxintomodulina.
RU2009111391A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
ES2673672T3 (es) Composiciones tripeptídicas y su uso para el tratamiento de la diabetes
ES2399651T3 (es) Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
ES2710948T3 (es) Composiciones y usos médicos de las mismas
US20090306209A1 (en) Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US20070254837A1 (en) Treatment for Necrotizing Enterocolitis
CA2588911A1 (fr) Compositions ou combinaisons nutritives therapeutiques et procedes d'utilisation
Jonas et al. Potential role of glutamine administration in inflammatory bowel disease
WO2024061919A1 (fr) Polythérapie
WO2018139477A1 (fr) Nouvel agent thérapeutique pour l'anémie néphrogénique ciblant un récepteur d'érythropoïétine via no et la stimulation de la voie no
JP2013501043A (ja) 経口投与可能な医薬製剤
Ahmed et al. Skeletal muscle clearance of L-alanyl-L-glutamine (ALA-GLN): in vitro peptidase activity of rat sarcolemmal vesicles
JP2013501043A5 (fr)
Guzmán et al. THE OXIDATIVE DAMAGE PATHWAYS OF GLUTAMINE IN SOME CLINICAL DISEASES
JPH10101576A (ja) 消化器疾患治療剤
Raul et al. Functional and metabolic changes in intestinal mucosa of rats by enteral diet supplemented with ornithine alpha-ketoglutarate salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008516083

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005332949

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005332949

Country of ref document: AU

Date of ref document: 20050616

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005332949

Country of ref document: AU

122 Ep: pct application non-entry in european phase

Ref document number: 05759320

Country of ref document: EP

Kind code of ref document: A1